Cord Blood. Investieren in die Zukunft von Morgen.
Seite 4 von 12 Neuester Beitrag: 24.04.21 23:29 | ||||
Eröffnet am: | 23.05.11 19:02 | von: brunneta | Anzahl Beiträge: | 296 |
Neuester Beitrag: | 24.04.21 23:29 | von: Melaniefoiza | Leser gesamt: | 58.686 |
Forum: | Hot-Stocks | Leser heute: | 12 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 | 6 | 7 | 8 | 9 | ... 12 > |
LAS VEGAS and BUENOS AIRES, Argentina, Sept. 27, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today updated shareholders on the progress of Biocordcell Argentina S.A. (BioCells, Inc.), which is 50.1 percent owned by Cord Blood America.
"January through August revenues in 2011 are up 40 percent to $1.18 million (U.S.)," said Diego Rissola, president of BioCells, Inc. "The increase in revenues reflects the fact that we have established franchises in six provinces in Argentina and we opened an office in Miami, Florida, to service the Latin American population there. We are now signing 11 percent more new contracts than we did in the same period in 2010."
"We have been successful with e-marketing, using a new web page and social media. We also now have operations in Brazil and the Dominican Republic, and the development of storing dental pulp is proving to be a potential revenue enhancer for the Company," Mr. Rissola said.
"BioCells of Argentina has performed fantastically in a down global economy. We''ve realized great growth, profitability, just a good story all around. We''re fortunate to have purchased the control position of this ever expanding company," said Matthew Schissler, CEO of Cord Blood America.
(Revenue and other financial estimates contained in this press release have not been audited or reviewed by Cord Blood America''s independent auditors. The Company provides no assurance that these preliminary results will not change following the completion of its financial audit for Fiscal 2011.)
http://www.finanznachrichten.de/...-shareholders-on-argentina-008.htm
Es hat mich einiges Geld gekostet, diese Erkenntnis zu erlangen.
Genta, Cord Blood...
Indikatoren:
- Finanzierungsmodellen über Aktienzuteilungen
- Reverse Splits
- keine signifikanten Erfolge
- hochtrabende Presseerklärungen
- Finanzierungsmodellen über Aktienzuteilungen
- Reverse Splits
- keine signifikanten Erfolge
- hochtrabende Presseerklärungen
- Finanzierungsmodellen über Aktienzuteilungen
- Reverse Splits
- keine signifikanten Erfolge
- hochtrabende Presseerklärungen
> Copy und Paste Problem?
Nein, das ist der Teufelskreislauf!
LAS VEGAS, Oct. 12, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord bloodstem cell preservation companyfocused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that its Board of Directors will conduct a process to explore and evaluate strategic alternatives for Cord Blood America to enhance shareholder value.
Cord Blood America has not set a timetable for completion of the evaluation process or made a decision to pursue any particular transaction or other alternative, and there can be no assurancethat any transaction or other alternative will be pursued or completed.
Cord Blood America does not intend to comment further regarding the evaluation of possible strategic alternatives, unless a specific transaction or process is concluded, or it otherwise deems further disclosure is appropriate or required.
About Cord Blood America
Cord Blood America is the parent company of CorCell, Companies, Inc., which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visithttp://www.cordblood-america.com/.
CONTACT: Paul Knopick
E & E Communications
(949) 707-5365
pknopick@eandecommunications.com
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America''s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company''s public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company''s past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE Cord Blood America, Inc.
© 2011 PR Newswire
kostet mich ja mehr die drecksscheine loszuwerden als sie noch wert sind sowas nennt man wohl totes investment und liegen in meinem depot bis ich sterbe, wenn sie nicht vorher gestrichen werden!
kostet mich ja mehr die drecksscheine loszuwerden als sie noch wert sind sowas nennt man wohl totes investment und liegen in meinem depot bis ich sterbe, wenn sie nicht vorher gestrichen werden!